X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing advances Evergreen's novel discovery pipeline into clinical trials, including its novel theragnostic pair, 177Lu-EVG-321 and 68Ga-EVG-321, a novel radiopharmaceutical drug, which, if successful, could offer new hope to patients with small cell lung cancer.
Lead Product(s): 177Lu-EVG-321
Therapeutic Area: Oncology Product Name: EVG-321
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Petrichor
Deal Size: $26.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 16, 2024
Details:
Under the terms of the agreement, Evergreen will develop 225Ac-FAP-2286 at its facility in Springeld, N.J. The facility was purpose-built to develop and manufacture a variety of therapeutic radiopharmaceuticals, including those based on alpha-emitting isotopes.
Lead Product(s): 225Ac-FAP-2286
Therapeutic Area: Oncology Product Name: 225Ac-FAP-2286
Highest Development Status: UndisclosedProduct Type: Peptide
Recipient: Clovis Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 16, 2022
Details:
The agreement with Evergreen provides long term commercial supply of iopofosine I-131 and supply of clinical study material for Cellectar’s pivotal study in Waldenstrom’s macroglobulinemia (WM) as well as ongoing Phase 1 and Phase 2 clinical studies.
Lead Product(s): Iopofosine I-131
Therapeutic Area: Oncology Product Name: CLR-131
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cellectar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 16, 2021
Details:
Under the terms of the deal, Evergreen will provide US-based manufacturing for Precirix’s lead product candidate, CAM-H2. CAM-H2 is being evaluated in a Phase I/II clinical trial targeting HER2-positive metastatic breast and gastric cancer.
Lead Product(s): 131-Iodine conjugated anti-HER2 sdAb 2Rs15d
Therapeutic Area: Oncology Product Name: CAM-H2
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Precirix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
